Essex Bio-Technology Limited operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Essex Bio-Technology Limited with three other
pharmaceutical manufacturers in Asia:
Walvax Biotechnology Company Limited
sales of 590.16 million Chinese Renmimbi [US$85.71 million]
of which 38%
was Autonomous Vaccine),
of South Korea
(124.19 billion Korean Won [US$111.15 million]
Panacea Biotec Ltd
based in India
(6.53 billion Indian Rupees [US$101.16 million]
of which 59%
Essex Bio-Technology Limited reported sales of HK$775.66 million (US$99.66 million)
December of 2016.
increase of 18.6%
versus 2015, when the company's sales were HK$654.01 million.
Sales at Essex Bio-Technology Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 265%).
Sales of Sales of Pharmaceutical Products saw an increase
20.7% in 2016, from
HK$602.84 million to HK$727.82 million.
Not all segments of Essex Bio-Technology Limited experienced an increase in sales in 2016:
sales of Other Businesses fell 6.5% to HK$47.85 million.